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Summary 
In vitro studies have revealed that help for cytotoxic T lymphocyte (CTL) induction can be mediated 
through several pathways, including direct recognition of allogeneic class II antigens by CD4 § 
cells, direct recognition of altogeneic class I antigens by "CD4-independent" CD8 + cells, and 
"indirect" recognition of peptides of alloantigens presented in association with self class II molecules. 
Whereas good evidence for the two direct pathways is available in vivo, there is relatively little 
evidence to show that indirect recognition can initiate graft rejection. This study examined the 
role of indirect allorecognition during the generation of CTLs in mice as they rejected major 
histocompatibility complex (MHC) class II-deficient skin after depletion of CD8 + T  cells in 
vivo. Recipients were depleted of CD8 + T cells by in vivo treatment with anti-CD8 monoclonal 
antibody and then grafted with allogeneic skin lacking MHC class II antigens. The mice rejected 
the skin grafts rapidly. Although flow cytometry showed marked depletion of CD8 + T  cells 
in these mice, we found that (a) CD8 + CTLs were generated and sensitized to MHC class I 
antigens of the donor; (b) the generation of the CD8 + CTLs required the help in vivo of CD4 + 
cells, as well as priming with the allogeneic skin graft; and (c) the CD4 + T  helper cells were 
sensitized indirectly to donor peptides presented in association with class II antigens on recipient 
antigen-presenting cells. These results provide evidence that indirect recognition can provide effective 
help for CTL induction during graft rejection, even when the cytotoxic T  cells are sensitized 
by determinants expressed only on the donor graft. 
I~ 
irect recognition describes the stimulation of recipient 
cells by allogeneic donor antigens presented in associa- 
tion with self MHC antigens on recipient APCs. Although 
indirect recognition represents the ordinary process by which 
T  cells are sensitized during normal immune responses, its 
contribution to graft rejection is obscured by the powerful 
direct stimulation of T  cells by donor APCs in allogeneic 
responses.  Although it has been known for a long time that 
indirect recognition can occur during rejection of foreign 
tissue,  and that it can play an effective role in allogeneic re- 
sponses  in vitro (1-3),  it has not been clear whether this 
pathway alone can actually initiate graft rejection in vivo. 
This uncertainty has been especially important when the donor 
and recipient have been MHC mismatched, such that the de- 
terminants formed on recipient APCs would not be expressed 
on the cells of the donor graft. 
The recent availability  of mice lacking MHC class II an- 
tigens has provided a new opportunity to examine the role 
of indirect recognition. Lacking class II antigens on their own 
APCs, grafts from these animals to normal recipients would 
be expected to stimulate CD4 + T  cells only by the presen- 
tation of donor peptides in association with recipient class 
II molecules. However, because these grafts still express class 
I  antigens, they can sensitize alloreactive CD8 + cytotoxic 
cells without the help of CD4 + cells. Thus, a direct pathway 
for rejection of a MHC-disparate graft can still  exist even 
when the donor lacks class II antigens, making it still difficult 
to demonstrate that indirect recognition alone can initiate 
graft destruction. 
To overcome this problem, we have recently performed and 
reported a series of in vivo experiments with class II-deficient 
donor skin grafts using two strategies to eliminate the direct 
pathway of donor antigen recognition (4). First, we used grafts 
without MHC antigen disparities and only minimal minor 
antigen differences to eliminate the direct CD8 § stimulation 
by donor class I antigens. Second, we treated mice with anti- 
CD8 antibody in vivo, forcing rejection of the class II-deficient 
grafts to depend on CD4 § cells. The results of these studies 
suggested that indirect recognition could effectively initiate 
rejection. 
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conclusion that indirect recognition can lead to rejection even 
when the donor and recipient are mismatched for their MHC 
antigens. We examined T cell responses in mice that had been 
treated with anti-CD8 antibody in vivo and that had rejected 
class II-deficient but class I-mismatched grafts. As expected 
from the previously published work of Rosenberg et al. (5), 
we found that despite the in vivo treatment with anti-CD8 
antibody, CD8 + CTLs were present in these mice after graft 
rejection. We found that these CTLs were specific for donor 
class I antigens and depended on CD4 + helper cells that had 
been sensitized by donor peptides presented by recipient class 
II molecules. These results confirm that indirect recognition 
can play an effective role in graft rejection. They also show 
that  CD4 +  cells  (sensitized  indirectly by recipient APCs) 
can  provide  help  for  CD8 +  CTLs  (sensitized  directly by 
donor cells), suggesting that four different cell types can work 
together to produce cytotoxic T  cells. 
Materials and Methods 
Animals.  BALB/cBy (H-2a),  C57BL/6J (H-2  b) (B6), B10.D2 
(H-2d), and [BALB/c  x  B6]F1 (H-2d/b), (CB6F1) mice were ob- 
tained from the Jackson Laboratory (Bar Harbor, ME). C3H/Sed 
(H-2  k) mice were supplied by the Edwin L. Steele Laboratory at 
Massachusetts  General Hospital (Boston, MA). The generation of 
[129  x  B6]F3 MHC class II knockout mice (H-2b), (II-) has been 
reported elsewhere (6). Briefly, the A~  b gene was disrupted in the 
D3 embryonic stem cell line of 129/Sv origin using the technique 
of homologous recombination. Cloned embryonic stem ceils ex- 
pressing the mutant gene were injected into B6 blastocysts and im- 
planted in foster mothers. A chimeric male founder animal was 
bred with a normal B6 female to select for germline transmission 
of the defective gene. Their offspring were intercrossed and those 
of their offspring which were homozygous for the mutant gene 
were selected as founders for further breeding. Mice of the next 
(and subsequent) generations expressed the class II deficiency and 
a random assortment of B6 and 129 genes, some homozygous and 
others still  heterozygous. These mice are referred to as F3 class 
II-deficient mice (II-).  For use in certain in vitro experiments, 
BALB/c mice were bred with F3 II-  mice to generate [BALB/c 
x  II-]F1 mice and 8th generation B6 class lI-deficient mice were 
generated by backcrossing onto a B6 background. 
Skin Grafting and Adult Thymectomy.  Skin grafts were placed 
on mice according to the technique of BiUingham  and Medawar 
(7). Mice were anesthetized with chloral hydrate supplemented with 
ether. Grafts were placed on the lateral  thoracic area and held in 
place with vaseline gauze and plaster bandages.  The bandages were 
removed on the seventh or eighth day. Rejection was recorded when 
there was >90% destruction of the tissue. Thymectomies were per- 
formed on mice using the suction pipette technique with ether 
anesthesia. 
mAbs and In Vivo T Cell Depletion.  Anti-CD8 (2.43) (8), anti- 
CD4 (GK1.5) (9), and anti-Thy 1.2 (H0 13-4) (10) ascites were pre- 
pared from hybridomas obtained from the American Type Culture 
Collection (Rockville, MD). Anti-CD3 (YCD3-1)  (11) ascites was 
prepared from a hybridoma kindly donated by K. Bottomly (Yale 
University, New Haven, CT). CD8 + T cells were depleted using 
the 2.43 (rat anti-mouse CDS) antibody, and CD4 § T cells were 
depleted using the GK 1.5 (rat anti-mouse CD4) antibody, as we 
have described previously (12). All treated mice were thymectomized 
before receiving 0.1 ml i.p.  of unpurified ascites of mAb on days 
-6,  -3,  and  -1 before skin transplantation. 
Anti-mouse  Surface Marker Reagents.  FITC-conjugated  rat 
anti-mouse Thy 1.2 and PE-conjugated rat anti-mouse Lyt 2 (mouse 
CD8),  purchased  from  Becton  Dickinson  Immunocytometry 
Systems (Mountain View,  CA), were used to stain  T  cells. 
Staining and Flow Cytometric Analysis.  FACS  |  medium (Becton 
Dickinson) containing lx  PBS, 0.1% fetal bovine albumin, and 
0.1% sodium azide was used. 3  x  105 cells were stained per well 
in 96-weU, U-bottomed plates.  Mouse FcyR were blocked with 
0.5/xg of 2.4G2 (13), a rat anti-mouse Fcq,  R  mAb.  Cells were 
then incubated with staining reagents for 30 min at 4~  The cells 
were washed twice with FACS  |  medium. All cells were fixed with 
2% paraformaldehyde for 30 min. Flow cytometric analysis was 
performed using a FACScan  |  flow cytometer (Becton Dickinson). 
Indirect staining was performed using a FITC-conjugated mouse 
antibody specific for rat IgG, H  and L chain (Jackson  Immuno- 
research Laboratories, Inc., West Grove, PA). For indirect staining, 
no blocking antibody was used. 
In Vitro Cytolytic Assay.  Responder spleen cells (7.5-25  x  106) 
were cocultured with irradiated (2,000 cGy) spleen stimulator cells 
(25  x  106) in  10-20-ml cultures of tissue  culture medium con- 
sisting of RPMI-1640 supplemented with 10% FCS, 20 mM Hepes, 
2 mM r-glutamine, 0.1  mM nonessential amino acids (all from 
GIBCO BRL, Gaithersburg, MD), 100 #g/ml gentamicin sulfate, 
and 0.05 mM 2-ME (both from Sigma Chemical Co., St. Louis, 
MO). After 5 d, cultures were assayed for cytolytic activity against 
51Cr-labeled Con A (Sigma Chemical Co.) or LPS (Difco Labora- 
tories, Detroit, MI) induced lymphoblasts as targets in a 4-h SlCr- 
release assay. Specific lysis was determined using the formula: [100 
x  (Experimental release  -  spontaneous release)/(maximum re- 
lease -  spontaneous release)]. In some assays 50 tzl of appropriate 
mAb (dilution of 1/200-1/400 ascites) was added to wells at the 
time of incubation with the targets. 
Mixed  Lymphocyte Reaction (MLRf.  Untreated  or  antibody 
plus complement-treated responder spleen  cells  (2  x  105) and 
stimulator spleen cells (4  x  105) (2,000 cGy) were added in a final 
vol of 200 #1 of tissue  culture medium to U-bottomed wells in 
triplicate.  The cultures were incubated at 37~  in a humidified 
air containing 5% CO2 for 3-4 d. [3H]TdR (1 #Ci/well; New En- 
gland Nuclear, Boston, MA) was added 12-14 h before the end 
of culture. The samples were harvested onto glass fiber filters, and 
[3H]TdR uptake was measured by 3  scintillation  counting on a 
RackBeta counter (model 1209; Pharmacia,  Gaithersburg, MD). 
Results are expressed as mean counts per minute +_ standard error 
of the mean. In certain assays, 50 #1 of the appropriate mAb in 
ascites (1/50 to 1/100 dilution) or culture supernatants (1/2-1/16 
dilution) was  added to the culture wells  for blockade. 
Antibody Plus Complement Depletion.  Spleen cells were resus- 
pended at a density of 50  x  106 cells/ml and incubated with ap- 
propriate antibody dilution or medium alone for 30 rain on ice. 
Cells were washed with medium, pelleted, resuspended,  and in- 
cubated with rabbit C' (C-6 Diagnostic, Inc., Mequon, WI) at 
a dilution of 1/5, at a density of 40  x  106 cells/ml, for 30 min 
at 37~  Control cultures contained complement alone. The cells 
were then washed twice and resuspended. 
Results 
Mice Treated With Anti-CD8 Antibody In Vivo Rejected Skin 
Grafts Lacking MHC Class II Antigens.  We have previously 
1 Abbreviation used in this paper: MLK, mixed lymphocyte reaction. 
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Figure  1.  Survival of MHC disparate tail skin grafts without class II 
antigens on recipients depleted of selected T cells. Tail skin grafts from 
F3 class II-deficient mice were transplanted to thymectomized BALB/c 
mice that  had been treated with  nothing  (-~-),  anti-CD4 antibody 
(--IS]--), anti-CD8 antibody (--C)--), or both antibodies (--A--). 
published results similar to those in Fig. 1 showing the sur- 
vival of MHC class II-deficient skin grafts placed on other- 
wise normal mice after depletion of CD4 + , CD8 + , or both 
T cell subpopulations (4). Grafts placed on recipients depleted 
of either subpopulation alone were rejected with only slight 
delay, whereas those on recipients depleted of both subpopu- 
lations showed prolonged survival. We were interested in ex- 
amining  more carefully the rejection observed after CD8 + 
T  cell depletion.  Whereas this rejection would seem to de- 
pend  entirely  on  CD4 §  T  cells,  even  though  the  grafts 
lacked MHC  class II antigens,  we were aware that Rosen- 
berg  et  al.  (5)  had  found  cytotoxic T  cells  derived  from 
CD8 + cells even in mice that had been treated in vivo with 
anti-CD8 antibody. We therefore tested mice from this group 
to determine whether they had CTLs and how they had been 
sensitized. 
Anti-CD8-treated  and Skin-grafted  Mice  Had Few  CD8 + 
Cells  But  Nonetheless  Generated  CD8 §  CTLs  Specific  for 
Donor Class 1Antigens.  Fig. 2 shows the results of flow cyto- 
metric analysis of mice with or without anti-CD8 treatment 
in vivo.  Normal mice have  '~10%  CD8 + Thyl.2 §  spleen 
cells whereas those treated with anti-CD8 antibody had <1%. 
Indirect staining showed no evidence for anti-CD8 antibody 
coating of the cells  (data not shown).  Even after rejection 
of grafts,  treated  mice had <1%  CD8 + Thy 1.2 + T  cells. 
Despite the apparent  effectiveness of CD8 depletion,  we 
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Figure 2.  Anti-CD8-treated  and 
II-  skin-grafted BALB/c mice 
possess very few  CD8 + T  cells. 
Representative two-color  flow  cyto- 
metric  analysis of splenocytes is 
shown.  (.4) Naive BALB/c mice 
have  11.0% CD8 +,  Thy  1.2 + 
splenocytes. (B)  II-  Skin-grafted 
BALB/c mice have 9.8% CD8 +, 
Thy 1.2 + splenocytes. (C)  Anti- 
CDS-treated,  ungrafted, BALB/c 
mice have 0.3% CD8 +  , Thy 1.2 + 
splenocytes. (D) Anti-CDS-treated 
and II- skin-grafted BALB/c  mice 
have  0.8%  CD8 +,  Thy  1.2 + 
splenocytes. 4-6 wk after treatment, 
splenocytes were stained with PE- 
anti-CD8  and FITC-anti-Thy 1.2 
antibodies, analyzed as described, 
and  presented in  log-log  scatter 
plots. 
867  Lee et al. found evidence for the presence of cytotoxic cells in  anti- 
CD8-treated BALB/c mice after rejection of MHC class II- 
skin.  When  spleen cells from  anti-CD8-treated  and  skin- 
grafted  mice  were boosted in  vitro  with  B6  stimulators, 
significant lysis was detected against B6 Con A blasts that 
express H-2  b class  I but not  class  II molecules (Fig.  3). 
The  CD8 +  CTLs  primed  by skin  grafting  could  have 
been sensitized directly by the donor H-2  b class I antigens 
expressed on donor APCs or indirectly by peptides of donor 
antigens  presented  by recipient  H-2 d class  I  antigens  ex- 
pressed on recipient APCs. To examine these two possibili- 
ties, we tested the specificity of the CD8 + CTLs primed in 
vivo.  As  shown  in  Fig.  3 B,  the  CTLs  killed B6  (H-2  b) 
targets well but not C3H (H-2  k) targets at all,  an unlikely 
event if they were sensitized to peptides plus H-2  d MHC an- 
tigens. In addition,  Fig. 3 C shows that the CTLs killed B6 
targets expressing H-2  b class I antigens but were unable to 
kill B10.D2 targets after in vitro boosting with B6 or B10.D2 
or [BALB/c  x  II-]F1  stimulators  (which would offer pep- 
tides of F3 antigens  in association with  self,  H-2  d class II 
molecules but would not express native H-2  b class II mole- 
cules). B10.D2 targets present B10 minor antigens in associ- 
ation with H-2  a class I antigens.  The complete absence of 
kill on both B10.D2 and C3H targets suggests that the CTLs 
were primed  in vivo by direct  sensitization  to donor class 
I antigens and not to self MHC antigens plus donor peptides. 
The data in Fig. 4  show that  the CTLs mediating  anti- 
class I responses in anti-CD8-treated  mice were CD8 +,  as 
the cytotoxicity was eliminated  with  anti-CD8  mAb plus 
C' treatment (Fig. 4 A) or anti-CD8 mAb blockade but not 
by anti-CD4 mAb blockade (Fig. 4 B). Thus, despite the sub- 
stantial  depletion  of CD8 + T  cells by antibody treatment 
in  vivo,  anti-CD8-treated,  skin-grafted  mice  did  possess 
CD8 + CTLs that were specific for donor classes I antigens. 
Generation of Anti-class I  CTLs in Anti-CDS-treated Mice 
Required In  Vivo Priming  With a Skin Graft and the Help of 
CD4 + Cells.  We next investigated whether generation  of 
the anti-class I CTLs required in vivo sensitization. We tested 
splenocytes from BALB/c mice that were thymectomized and 
treated in vivo with anti-CD8 mAb but that had not received 
a skin graft. We found no CTL activity after in vitro stimu- 
lation with B6 splenocytes (Fig.  5 A). Thus,  the ability to 
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Figure  3.  Anti-CD8-treated and 
skin-grafted  BALB/c  mice  have 
CTLs specific for donor class I an- 
tigens. Splenocytes from anti-CD8- 
treated  and  skin-grafted  BALB/c 
mice were cultured with irradiated 
stimulator cells. After 5 d in culture, 
effector cells were harvested and as- 
sessed for generation of CTLs. (A) 
CTLs from anti-CD8-treated and 
skin-grafted BALB/c mice (-l-) 
versus control-untreated but skin- 
grafted BALB/c mice (--A--).  (B) 
Effector cells from anti-CD8-treated 
and skin-grafted BALB/c mice tested 
against  con  A  B6  (H-2  b)  targets 
(-D-), self BALBIc (H-2  d) (--[]--), 
and third-party C3H (H-2  k) (-O-) 
targets. (C) Responders from anti- 
CD8-treated  and  skin-grafted 
BALB/c mice were cultured with 
stimulators from B6 (--B-, -[3--), 
B10.D2  (--O--,  --A--),  and 
[BALB/c  x  II-]Vl  (-A--)  mice 
and tested against B6  (-I-)  and 
B10.D2 (--D--, --O--, --A--) tar- 
gets. Control CTL activity of B6 
responders cultured with  B10.D2 
stimulators and tested against B10.D2 
targets (--A--) is shown. A 
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Figure  4.  The CTLs from anti- 
CDS-treated  and  skin-grafted 
BALB/c mice are CD8 +. After 5 d 
of  MLC  (A)  effector  cells  were 
depleted oft cell subpopulations be- 
fore their incubation with B6 targets 
by treatment with anti-CD8 (2.43) 
mAb  +  C'  (--O--),  anti-Thy 1.2 
(HO-13.4)  +  C' (--A--), or with 
C'  alone  (-J~);  or  (B)  effector 
cells were incubated with anti-CD8 
(2.43)  mAb (--A--), antbCD4 mAb 
(GK1.5)  (--F%-),  anti-CD3 
(YCD3-1) (--O--), or with no mAb 
(-l-)  during the 4-h SlCr-release 
assay. 
detect anti-class  I CTLs in anti-CD8-treated mice required 
that these CTLs be primed in vivo by the MHC class II- 
skin graft. 
These CD8 + CTLs might have been derived from the so- 
called "helper-independent" CD8 + population that does not 
require help from CD4 + T  cells (14).  However, as shown 
earlier in Fig.  1, BALB/c mice treated simultaneously with 
anti-CD4 and anti-CD8 mAb before skin grafting retained 
A 
80 
6O 
~,  40 
~  2o 
B 
80 
60 ￿84 
'~  40 
._1 
W  20 
80  40  20  10 
Effector/Target 
80  40  20  10 
Effector/Target 
In vivo Rx  In vivo Graft  In vitro Stimulator 
Anti-CD8  ll-  B6 
Anti-CD8  None  B6 
I..11. vivo Rx  In vivo Graft  In vitro Stimulator 
Anti-CD8 +  II-  B6 
Anti-CD4 
Anti-CD8  11-  B6 
In vitro Rx 
In vitro Rx 
Target 
B6  = 
86  --'O--" 
Target 
B6  --'O'-" 
B6  ~" 
Figure  5.  Generation  of CTLs 
after anti-CD8 treatment in vivo re- 
quires in vivo priming and CD4 + 
T  cells.  (.4) Splenocytes from anti- 
CD8-treated,  ungrafted,  thymec- 
tomized BALB/c mice (--O--) and 
from  anti-CD8-treated,  skin- 
grafted BALB/c mice (-I1-) were 
cultured with B6  stimulators and 
tested  for  lyric  activity  against 
B6 Con A  blasts. (B)  Splenocytes 
from anti-CD8 +  anti-CD4-treated 
BALB/c mice that were grafted with 
II-  skin  (--I--)  and  from  anti- 
CD8-treated and skin-grafted mice 
(-tl-) were tested for anti-B6 kill. 
869  Lee et  al. their grafts for more than 50 d, suggesting that CD4 + cells 
are required for graft rejection in CDS-depleted mice. In ad- 
dition, as shown in Fig. 5 B, splenocytes from anti-CD4 plus 
anti-CDS-treated mice did not show eytotoxic activity against 
B6 Con A targets. Thus, CTL generation in anti-CD8-treated 
and  skin-grafted mice was dependent upon  CD4 + helper 
cells in vivo. 
The CD4 § Helper T  Cells in Anti-CD8-treated, Skin-grafted 
Mice Responded  to Peptides of Donor Antigen Presented in As- 
sociation With Recipient Class H Antigen.  Since the skin grafts 
in these experiments lacked class II antigens, we presumed 
that the CD4 + helper population responded to donor an- 
tigens presented by the class II antigens on recipient APCs. 
Further in vitro experiments were performed to test this hy- 
pothesis. 
To examine CD4 + T  cell responses, we used anti-CD8- 
treated BALB/c mice that had been grafted with skin from 
B6 class II-deficient mice. We reasoned that if CD4 + cells 
were sensitized indirectly to donor antigens by recipient class 
II molecules, these mice would respond to B10.D2  stimu- 
lators in an MLtL. Fig. 6 shows that CD4 + cells from anti- 
CD8-treated and skin-grafted BALB/c responders responded 
to donor antigens presented in association with self, H-2 a 
class II molecules. They did not respond, even after graft re- 
jection, to B6 class II-deficient stimulators.  Naive BALB/c 
responders did not respond to B10.D2 stimulators,  as expected 
in the case of minor antigen disparities.  Variations of this 
experiment  have  been  performed five  times.  CD4 +  cells 
from mice that had rejected class II-deficient grafts always 
responded to donor antigens presented by cells expressing 
recipient MHC antigens, and never responded to cells from 
the original class II-deficient donor. Thus, these in vitro data 
suggest that the CD4 + cells in these recipients were sensi- 
tized by indirect recognition. 
RESPONDER  A. NAIVE  B. ANTI-CD8 + 
II- SKIN GRAFT 
IN  VITRO  Ab  NONE  NONE 
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Discussion 
The primary conclusion from the in vitro evidence in this 
paper is that indirect recognition alone can sensitize CD4 + 
helper cells that effectively initiate graft rejection. Whereas 
this  conclusion  has  long  been  suspected,  until  now  the 
powerful direct stimulation provided by donor class II an- 
tigens has made it difficult to examine the independent im- 
portance of the indirect pathway. The availability of the MHC 
class II knockout mice has provided a remarkable tool for 
studying this aspect of the mechanism of graft rejection. 
The second conclusion from these data is that indirect rec- 
ognition sensitizing CD4 § helper cells to determinants ex- 
pressed on recipient APCs can provide help for CD8 + cyto- 
toxic cells sensitized to determinants expressed only on donor 
cells. Thus, four different cell types can be involved in the 
development of mature CTLs: CD4 § cells, recipient APCs, 
CD8 + cells, and donor APCs. This conclusion is important 
because most previous evidence has suggested that helper cells 
can only interact effectively in vivo with precursor effector 
cells if they are brought physically together in a three-cell 
cluster by a single APC. 
Mitchison and O'Malley (15) first characterized the need 
for a "three cell-type cluster" to generate in vivo cytolytic 
responses. The principle has also been suggested as a require- 
ment for other helper T cell interactions with effector popu- 
lations (16-18).  Furthermore, the idea that helper and cyto- 
toxic determinants must be expressed on the same APC to 
bring cooperating T cells together is consistent with several 
previous observations regarding in vivo allogeneic responses. 
For example, Keene and Forman (19) have shown that in vivo 
generation of anti-Qal CTLs requires that the H-Y helper 
determinant and the Qa-1 CTL determinant be presented on 
the same immunizing cell, and Rosenberg et al. (20) showed 
that the helper determinant on bm12 antigens had to be coex- 
pressed with eytotoxic determinants of bin6 on the same graft 
in order to produce rejection ofa bm6 graft by B6 mice. They 
C. ANTI-CD8 + 
II- SKIN GRAFT  found similar results with respect to Qa-1 and H-Y anti- 
ANTI-CD4  gens (20). 
The finding in this paper that four cell types can partici- 
pate in CTL priming seems to contradict the evidence for 
a physical linkage of helper and cytotoxic determinants and 
suggests a model that would seem to be inherently unstable. 
If CD4 + T cells, interacting with self APCs in one part of 
the body, can provide help for CD8 §  T  cells,  interacting 
with donor APCs in another location, then there should be 
no requirement that the peptides presented by the self APCs 
~  need even be derived from the graft. Any immune stimulus 
should be capable of helping the CTL response, a situation 
that would seem highly chaotic, not only with respect to 
,-  graft rejection, but for all quiescent T  cell responses. 
'  "  '  ~  There are, however, at least two reasonable hypotheses to  ~.  ~  =  . 
c)  o 
7~  ~  ~,  explain our findings without contradicting previous obser- 
vations.  First,  the four-cell phenomenon may only be ob- 
servable when there are large numbers of antigen disparities 
during graft rejection. Most previous in vivo studies sug- 
gesting a physical linkage have used only a single H-Y (19, 
20), Qa (19, 20), mutant class I or II antigen (20) disparity. 
Perhaps the large number of minor antigen disparities in- 
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Figure  6.  MLR of BALB/c mice after anti-CD8 treatment and skin 
grafting.  (.4) Naive BALB/c,  (B) anti-CDS-treated and 8th generation 
B6 II- skin-grafted  BALB/c, and (C) anti-CDS-treated and skin-grafted 
BALB/c responders plus in vitro anti-CD4 mAb (GK 1.5) tested against 
self, B6 II-, and B10.D2 irradiated  stimulators.  Proliferation  was mea- 
sured by [3H]TdR  uptake. 
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Figure  7.  A four-cell  cluster model of recipient CD4 § T cell, recip- 
ient CD8 + T cell, recipient B cell, and donor APC for CTL sensitiza- 
tion in vivo. A responding B cell binds through its surface Ig receptor 
to the class I antigen  on the donor APC and presents donor antigens  to 
a CD4 + T cell. The CD4 + T cell provides help to a nearby CD8 + T 
cell that is being primed to the class I antigen  on the donor APC. Three 
sets of cognate interactions maintain the four-cell  duster. 
volved in our studies provided such a huge indirect immune 
stimulus in the draining LNs of a graft bed that CTLs con- 
tacting donor APCs in the same location were able to receive 
sufficient help from nearby CD4 + T cells that were primed 
to donor antigens processed  on recipient MHC molecules. 
Mitchison and O'MaUey (15) have  reported that epitope linkage 
in a three-cell cluster is not required in the setting of high 
concentrations of stimulating antigens, a finding that is con- 
sistent with this explanation. In their adoptive transfer studies, 
high  concentrations  (107) of a  one-to-one  mixture  con- 
taining one cell type expressing helper determinants and an- 
other cell type expressing a eytotoxic determinant generated 
CTLs in vivo. 
Alternatively, the principle of physical linkage would be 
maintained, even if four cells were involved in T cell priming, 
if the recipient APC must be a B cell.  As diagrammed in 
Fig. 7, a recipient B cell, bound to a donor-stimulating cell 
by a surface receptor for donor class I antigen, could present 
donor peptides in association with its own class II antigens 
to recipient CD4 + cells to form a four cell-type cluster. This 
would hold the CD4 § T  cell in close proximity to a recip- 
ient  CD8 §  CTL  recognizing  the  donor  antigens.  This 
model would thus prevent nonspecific T  cell activation. It 
would also predict that four cells could lead to T cell priming 
only under circumstances in which a B cell response was pos- 
sible, which is in keeping with the available data. No B cell 
response is measurable in the case of H-Y, Qa, or the narrow 
antigenic disparity generated by the mutant bm6 antigen, 
but anti-H-2  b class I antibodies are generated in anti-CD8- 
treated BALB/c mice after rejection of class II-deficient skin 
grafts (Lee, R., unpublished observations). We are currently 
attempting to determine whether CTLs can be generated by 
mice that have no B cells. 
Whatever the mechanism by which four cells together lead 
to CTL activation, the evidence that they can do so has im- 
portant implications for our understanding of graft rejection. 
For years there has been ongoing uncertainty about whether 
T cells primed indirectly by donor antigens presented by re- 
cipient APCs could play a role in generating donor-specific 
CTLs if the donor was MHC disparate.  If they cannot, then 
the indirect pathway for initiating rejection could not play 
a role in a cytotoxic rejection mechanism whenever the donor 
was MHC mismatched. Our findings, however, suggest that 
the indirect pathway is always available for generating donor- 
reactive  CTLs under some circumstances. 
Another implication is that APC depletion from a donor 
graft may not always prevent CTL generation because  the 
indirect pathway is still available to generate help. Several early 
studies have suggested a role for indirect recognition in the 
rejection of APC-depleted grafts (21-24),  such as La Rosa 
and Talmage's  (21) suggestion that indirect recognition of 
minor histocompatibility antigens from APC-depleted thy- 
roid grafts might be responsible for graft rejection. In light 
of our data, it would appear that neither depletion of donor 
APCs before transplantation, nor their replacement by recip- 
ient APCs after transplantation, can permanently remove the 
stimulus  for  productive  CD4 §  helper  T  cell  activation. 
Donor APC depletion may temporarily diminish indirect pre- 
sentation if the donor APCs are initially required as the ve- 
hicles to transport donor antigens to draining LNs. Alterna- 
tively, the effectiveness of donor APC depletion may depend 
primarily on its effect on CD8 + T  cells. If APC depletion 
induces anergy of CD8 + T  cells, then graft rejection may 
not occur, but if any stimulus for CD8 + activation remains, 
perhaps  by  "semi-professional" APCs  (25),  then  CD4 + 
helper cells, sensitized through the indirect pathway, should 
be available to help these CD8 + cells cause graft rejection. 
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